Edition:
United Kingdom

Manas Mishra

Teens with illnesses want role in decision-making

10 Sep 2019

(Reuters Health) - Teens with chronic illnesses would like to have a say in decisions such as switching to a new medicine, but they often feel left out of the conversation, a small study suggests.

Los Angeles County resident dies of lung illness, fifth U.S. death possibly tied to vaping

11 Sep 2019

A Los Angeles County resident has died from a lung illness possibly tied to vaping, bringing the total number of such U.S. deaths to five, health officials said on Friday. | Video

Mallinckrodt downplays bankruptcy fears, says hires advisers 'all the time'

06 Sep 2019

Mallinckrodt Plc on Thursday downplayed a media report that the company had hired restructuring firms and may choose to seek bankruptcy protection.

Patent court to review Alexion's Soliris patents on Amgen challenge

31 Aug 2019

The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

26 Aug 2019

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Parents can do better to keep their pot away from children

23 Aug 2019

(Reuters Health) - As legal cannabis use becomes increasingly common in the U.S., most parents say they keep their pot out of children's reach, but fewer keep it locked away, a study in Colorado suggests.

Sarepta shares sink 14% after shock FDA rejection

20 Aug 2019

Shares of Sarepta Therapeutics Inc plunged 14% on Tuesday after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

Sarepta shares sink 17% after shock FDA rejection

20 Aug 2019

Aug 20 Shares of Sarepta Therapeutics Inc plummeted 17% on Tuesday after the U.S. health regulator, in a surprise move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

UPDATE 2-U.S. FDA declines to approve Sarepta's second Duchenne treatment

20 Aug 2019

Aug 19 Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

Sick hospital workers often expose patients to contagious illness

16 Aug 2019

Hospital workers often come to work with contagious respiratory illnesses, against the recommendations of public health regulators, a Canadian study suggests.

World News